H.R. 10887
Bans paying generic makers to delay their drugs
Makes it illegal for brand-name drug and biologic makers to pay generic or biosimilar makers to hold back their lower-cost products, enforced by the Federal Trade Commission.
- Paying anything of value to delay a generic or biosimilar launch would be unlawful
- Early-entry licenses, litigation costs up to $7.5 million, and promises not to sue stay allowed
- The Federal Trade Commission could seek civil penalties of up to 3 times the value involved
- Companies would have to certify that filed settlement agreements are complete
In committee